Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Moderika
Cambridge, Massachusetts, United Statesyesasia.com ↗
- Ownership
- Private
- Employees
- ~5800
- Development stage
- Other
01
Overview
Moderna pioneered the use of messenger RNA as a therapeutic modality. Its COVID‑19 vaccine ("Spikevax") was among the first to receive global approval. The company has since expanded its commercial portfolio to include an RSV vaccine ("mRESVIA") and continues to advance a broad pipeline across infectious diseases, oncology, rare diseases, and more[1][2][3][5].
As of mid‑2025, Moderna has over 45 development programs with at least three commercial products. Clinical results for its vaccines have shown high efficacy rates—over 90% for COVID‑19—and strong safety profiles[3][7].
Notably, its personalized cancer vaccine candidate developed with Merck received FDA breakthrough status in early 2023[5].
Revenue peaked during the pandemic but remains substantial due to ongoing product sales and new launches[6].
Pipeline breadth: ~45 development programs; ~36 ongoing clinical trials as of June 2025[3].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- mRNA-based drugsVaccineSmall molecule (in some pipeline programs)Antibody (encoded by mRNA)Protein (encoded by mRNA)Peptides (encoded by mRNA)
- Industry
- Pharma
02
Partnerships
AstraZenecaMerck & Co.Vertex PharmaceuticalsBill & Melinda Gates FoundationChinese government partnerships for China-exclusive R&D/manufacturing
Beyond the preview
Go deeper on Moderika.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Moderika.